| abstract |
The invention provides a polypeptide comprising an apelic peptide, fused to a multimerizing component. The invention also provides a polypeptide comprising an apelin peptide fused to an Fc domain, a fragment of an Fc domain, or a variant of the Fc domain. Apeline peptides, fused to the Fc domain, are able to bind to apelin receptors (APLNR). Apelinic peptides, fused to the Fc domain, are able to activate APLNR and improve pharmacokinetic properties compared to the apelinic peptides that are not fused to the Fc or the Fc fragment. APLNR-binding agents are useful for alleviating cardiovascular diseases, as well as cancer and diabetes, among other diseases associated with apelin. |